Sandesh Mahatme has replaced Tony Martignetti as Sarepta Therapeutics' (NASDAQ:SRPT) chief accounting officer, the biotech said in a late Friday 8-K filing with the SEC. He will also remain as Serapta's chief financial officer.
Mahate joined Sarepta, a biotech specializing in therapies for genetic disorders such as Duchenne muscular dystrophy, last November from Celgene.
Martignetti's LinkedIn profile shows he'd been at Sarepta since September 2012. He joined the company after three years as managing partner at a real estate company and, before that, 1.5 years in commercial finance at Vertex Pharmaceuticals.
More than 37% of Sarepta's shares were sold short as of Oct. 1, making it one of the Nasdaq's five-most shorted stocks.
Fool contributor Tim Beyers is a member of the Motley Fool Rule Breakers stock-picking team and the Motley Fool Supernova Odyssey I mission. He didn't own shares in any of the companies mentioned in this article at the time of publication. Check out Tim's Web home and portfolio holdings, or connect with him on Google+, Tumblr, or Twitter, where he goes by @milehighfool. You can also get his insights delivered directly to your RSS reader.
The Motley Fool recommends Celgene, LinkedIn, and Vertex Pharmaceuticals and owns shares of LinkedIn. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.